YIR 2017 Neurology

Do Certain Medications Increase the Risk of MS Development?

By December 07, 2017

No drug treatments were conclusively associated with an increased risk of MS.

Soliris Approved to Treat Generalized Myasthenia Gravis

By October 24, 2017

The FDA based its approval of the extended indication for Soliris on comprehensive clinical data from the Phase 3, randomized, double-blind, placebo-controlled, multicenter REGAIN study (ECU-MG-301).

FDA Approves Treatment for Two Neuropathic Pain Conditions

By October 12, 2017

The efficacy of Lyrica CR has not been established for the management of fibromyalgia or as adjunctive therapy for adult patients with partial onset seizures.

Adverse Effects Compared for Multiple Parkinson's Disease Drugs

September 21, 2017

The researchers found that, compared with placebo, the incidence of adverse reactions of ropinirole, rotigotine, entacapone, and sumanirole were higher in terms of nausea.

Gocovri Approved to Treat Dyskinesia in Patients with Parkinson's Disease

By August 28, 2017

The safety and efficacy of Gocovri was seen in two Phase 3 controlled trials in Parkinson's disease patients with dyskinesia.

Law Enforcement Data Indicate a Rise in Gabapentin Misuse

By May 15, 2017

Using data from the Drug Diversion Program of the Researched Abuse, Diversion, and Addiction-Related Surveillance System, the authors were able to calculate the rates of gabapentin diversion (per 100,000 population) for each quarter from 2002-2015

FDA Approves First New ALS Drug in Over 20 Years

By May 08, 2017

The FDA's decision was supported by data from a clinical development program that lasted 13 years with multiple Phase 3 studies.

Austedo Approved for Huntington's Disease

By April 04, 2017

Austedo, a vesicular monoamine transporter 2 (VMAT2) inhibitor, is the first deuterated product approved by the FDA.

Ocrevus Approved for Relapsing, Primary Progressive MS

By March 29, 2017

This is the first drug approved for primary progressive MS.

FDA Approves New Parkinson's Disease Treatment

By March 21, 2017

Data showed Xadago statistically and significantly increased "on" time without troublesome dyskinesia.